For laboratory and research use only. Not for human consumption.
Growth Hormone

Tesamorelin

Also known as: Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8

FDA Approved
Share:
Last reviewed

Buy in shop

Tesamorelin

5 verified vendors, side by side on real prices.

Compare prices

Key Facts: Tesamorelin

Category
Growth Hormone
FDA Status
FDA Approved
Clinical Status
FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved)
Banned in Sport (WADA)
Prohibited at all times under WADA S2 (GHRH analogues), named on the list despite its FDA approval.
Administration
Subcutaneous injection
Typical Dose
2 mg daily (F8: 1.28 mg daily)
Frequency
Once daily
Duration
Indefinite for approved indication
Also Known As
Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8

How does Tesamorelin work?

Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies.

What does the research show?

The approval rests on real randomized, placebo-controlled human trials. The pivotal study by Falutz and colleagues (New England Journal of Medicine, 2007) showed that six months of tesamorelin selectively reduced visceral abdominal fat in HIV patients while improving lipid profiles, without meaningful harm to blood sugar control. Later randomized work (including a JAMA-published trial led by Stanley) confirmed reductions in visceral fat and liver fat. A small placebo-controlled study in non-HIV adults with abdominal obesity also found a meaningful visceral fat reduction over 26 weeks, hinting at broader potential, though that is far less established than the HIV indication. Side effects can include joint pain, swelling, and increases in IGF-1, and growth-hormone-axis drugs warrant caution in people with cancer history or uncontrolled diabetes. In short: well proven for HIV-associated visceral fat, promising but not approved for general use.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

What doses have been studied?

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

2 mg daily (F8: 1.28 mg daily)

Range

1.28-2 mg daily

Frequency

Once daily

The approved amount is 2 mg for the original formulation and 1.28 mg for the F8 (Egrifta WR) formulation. F8 is reconstituted weekly rather than daily.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Indefinite for approved indication

Administration

Subcutaneous injection

When and how is Tesamorelin taken?

Best Time to Take

Before bed (fasted)

Once daily before bed

Food Recommendation

Take on empty stomach

Why This Timing?

FDA-approved GHRH analog works best on empty stomach, timed with natural GH release during sleep.

What are the side effects of Tesamorelin?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Injection site reactions (common)
  • ●Joint pain
  • ●Peripheral edema
  • ●Pain in extremities
  • ●Muscle pain
  • ●Increased diabetes risk
  • ●May elevate blood glucose
  • ●Allergic reactions including anaphylaxis (rare)

References

Research This Peptide Further

Buy in shop

Tesamorelin

5 verified vendors, side by side on real prices.

Compare prices

Frequently Asked Questions

What does Tesamorelin do?

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.

How does Tesamorelin work?

Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies.

Is Tesamorelin FDA approved?

Yes, Tesamorelin is FDA approved. FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved)

Is Tesamorelin banned in sport?

Prohibited at all times under WADA S2 (GHRH analogues), named on the list despite its FDA approval.

What are the side effects of Tesamorelin?

Reported side effects include: Injection site reactions (common), Joint pain, Peripheral edema, Pain in extremities, Muscle pain. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Tesamorelin?

Community-reported common dose: 2 mg daily (F8: 1.28 mg daily) (Once daily). Range: 1.28-2 mg daily. Administration: Subcutaneous injection. Prescription drug. Dose set by prescriber per label. Not medical advice.

Related Peptides

Peptides commonly compared with Tesamorelin or used in similar applications.

HGH (Somatropin)

FDA

Human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. It is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. Almost everything you read about HGH for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used.

Growth Hormone

Mecasermin

FDA

Mecasermin is recombinant human IGF-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. Sold as Increlex, it was FDA approved in 2005 for a narrow group: children with severe primary IGF-1 deficiency (mostly Laron syndrome) or a growth hormone gene deletion with antibodies against GH. In those kids it is the only thing that works, because GH cannot do its job. It is not a GH substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug.

Growth Hormone

Ipamorelin

Clinical Trials

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.

Growth Hormone

MK-677

Clinical Trials

MK-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. Taken as a daily pill, it reliably pushes up growth hormone and IGF-1 levels, which is why it is popular for muscle and recovery. It has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and Alzheimer's came up short.

Growth Hormone

CJC-1295 (No DAC)

Clinical Trials

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29). The name covers two different products. CJC-1295 with DAC (Drug Affinity Complex) binds blood albumin, which stretches its half-life to roughly 6 to 8 days and raises GH and IGF-I for days from a single injection; this is the version ConjuChem took to Phase II before abandoning it, and the version the human data are about. CJC-1295 without DAC (Modified GRF 1-29, the form this page is named for) lacks the albumin tether and is much shorter acting, though its human half-life has not been formally published. Neither is an approved drug, both are sold only as research chemicals, and GHRH analogs are banned in sport by WADA.

Growth Hormone

GHRP-6

Clinical Trials

GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.

Growth Hormone

Want updates on Tesamorelin research?

Get an email when we add new research here, when it is back in stock, or when the price drops.